ABSTRACT
BACKGROUND: COVID-19 has been linked to a variety of dermatological conditions. OBJECTIVE: To determine the presence of various cutaneous manifestations in patients with COVID-19, also to define their features in relation to the systemic symptoms. METHODS: This research enrolled a total of 1206 lab-confirmed COVID-19 individuals at a tertiary-care hospital in Karachi, Pakistan. Expert dermatologists assessed patients for COVID-related skin conditions. COVID-19 severity was categorized as asymptomatic/mild, moderate, or severe. RESULTS: Of the 102 (85.7%) patients with only one cutaneous sign, 26.5% developed maculopapular/morbiliform/erythematous rash; 14.7% urticaria; 9.85% vesicular/pustular exanthem; 14.7% vascular pattern; 12.7% infections, 7.8% miscellaneous and 9.8% late cutaneous findings A longer-lasting vascular pattern was related with an older age and a fatal COVID-19 outcomes (P: 0.000) compared with mild/moderate disease. Most of the retiform purpura presented exclusively with thromboembolic episodes. The moderate severity was correlated with maculopapular/morbiliform/exanthematous phenotype (P: 0.009), whereas urticaria was attributed to asymptomatic/mild disease (0.001) compared with moderate/severe infection. LIMITATIONS: Single-Center and observational study. CONCLUSION: Vascular lesions were correlated with disastrous COVID-19 outcomes, whereas retiform purpura was linked to adverse outcomes. The maculopapular/morbiliform/erythematous rash was associated with moderate severity, while the urticarial rash was linked to milder course compared with moderate/severe severity infection.
Subject(s)
COVID-19 , Drug Eruptions , Exanthema , Purpura , Urticaria , COVID-19/complications , Exanthema/diagnosis , Exanthema/etiology , Humans , SARS-CoV-2 , Urticaria/etiologySubject(s)
COVID-19 , Drug Eruptions , Lichen Planus , Vaccines , Antibodies, Viral , COVID-19/prevention & control , Drug Eruptions/etiology , Humans , RNA, Messenger , SARS-CoV-2ABSTRACT
Unusual manifestations are possible for multi-system inflammatory syndrome brought on by SARS-Cov2 infection. Early diagnosis and effective treatment have a direct impact on the outcome. Every young patient who presents to the clinic with a fever, skin rash, stomach discomfort, or cardiovascular complications has to be evaluated for this potentially fatal disease. It is also of utmost importance to differentiate MIS-C from drug hypersensitivity (DHS). MIS-c highly resembles DHS but leads to more complications and a higher mortality rate. We report a 9-year-old female who initially presented with generalized abdominal pain, nausea, vomiting, and cough. She gradually developed an acute abdomen and was admitted for surgical management of a suspected perforated appendix. Her condition deteriorated despite surgery and medical treatment. Differentiating drug allergy from this new emerging syndrome can be difficult. Herein we discuss about it.
Subject(s)
Abdominal Pain , Cryopyrin-Associated Periodic Syndromes , Exanthema , Cardiovascular Diseases , Fever , Severe Acute Respiratory Syndrome , Nausea , Emergencies , Dementia, Multi-Infarct , Drug Hypersensitivity , Vomiting , Drug EruptionsABSTRACT
A fixed drug eruption (FDE) is a common cutaneous adverse drug reaction which occurs following administration of an offending drug. The aim of this review is to provide an update on the list of drugs causing FDE, with a focus on emerging drug culprits reported since the start of the century. Across published literature, triggers for FDE are widely varied. The most frequently implicated drugs include analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs] and paracetamol) and antibiotics. Co-trimoxazole is perhaps the most well described single agent. Since the start of the century there have been over 200 drugs named in case reports on FDE. Newer, novel agents of note include cyclooxygenase-2 specific inhibitors, fluconazole, and phosphodiesterase 5 inhibitors. Other implicated drugs include vaccines, such as various SARS-CoV-2 vaccines. Drugs incriminated in FDE vary based on the geographical region studied and prescribing patterns at a given time. Newer drugs continue to enter the market and are playing an increasing role in the field of FDE. Awareness of rarer culprits and emerging novel agents can help identify a trigger, allowing for prompt withdrawal of the causative agent, preventing recurrence.
Subject(s)
COVID-19 Vaccines , COVID-19 , Drug Eruptions , Humans , Acetaminophen/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , COVID-19 Vaccines/adverse effects , Cyclooxygenase 2/therapeutic use , Drug Eruptions/diagnosis , Drug Eruptions/drug therapy , Drug Eruptions/etiology , Fluconazole/therapeutic use , Phosphodiesterase 5 Inhibitors/therapeutic use , SARS-CoV-2 , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effectsABSTRACT
Coastal communities are highly exposed to ocean- and climate-related hazards but often lack an accurate population and infrastructure database. On January 15, 2022 and for many days thereafter, the Kingdom of Tonga was cut off from the rest of the world by a destructive tsunami associated with the Hunga Tonga Hunga Ha’apai volcanic eruption. This situation was made worse by COVID-19-related lockdowns and no precise idea of the magnitude and pattern of destruction incurred. The occurrence of such events in remote island communities highlights the need for (1) precisely knowing the distribution of residential and public buildings, and (2) evaluating what proportion of those would be vulnerable to a tsunami. A GIS-based dasymetric mapping method, previously tested in New Caledonia for assessing and calibrating population distribution at high resolution, is improved and implemented in less than a day to jointly map population clusters and critical elevation contours based on runup scenarios, and is tested against destruction patterns independently recorded in Tonga after the two recent tsunamis of 2009 and 2022. Results show that 62% of the population of Tonga lives in well-defined clusters between sea level and the 15 m elevation contour. The patterns of vulnerability thus obtained for each island of the archipelago allow exposure and potential for cumulative damage to be ranked as a function of tsunami magnitude and source-area. By relying on low-cost tools and incomplete datasets for rapid implementation in the context of natural disasters, this approach works for all types of natural hazards, is easily transferable to other insular settings, can assist in guiding emergency rescue targets, and can help to elaborate future land-use planning priorities for disaster risk reduction purposes.
Subject(s)
COVID-19 , Drug Eruptions , Communication DisordersSubject(s)
COVID-19 , Drug Eruptions , BNT162 Vaccine , Drug Eruptions/diagnosis , Drug Eruptions/etiology , HumansSubject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Drug Eruptions/etiology , Adult , Aged , Aged, 80 and over , BNT162 Vaccine/adverse effects , ChAdOx1 nCoV-19/adverse effects , Drug Eruptions/drug therapy , Drug Eruptions/pathology , Drug Eruptions/physiopathology , Female , Glucocorticoids/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Male , Middle Aged , Phenotype , SARS-CoV-2 , Young AdultABSTRACT
Favipiravir (FVP) has been used for treatment of COVID-19 in many countries. We analysed the incidence of FVP-induced cutaneous adverse reactions (CARs) in patients infected with COVID-19 who were hospitalized at Bamrasnaradura Infectious Diseases Institute, a principal centre of emerging infectious disease in Thailand, and who presented with cutaneous eruption following FVP prescription. We identified five cases of FVP-induced CARs: two patients with maculopapular rash, two with urticarial rash, and one with Stevens-Johnson syndrome. The median interval between FVP treatment and rash occurrence was 7 days and the mean duration of the rash was 5 days. This report highlights that FVP can induce CARs, particularly eruptions, in COVID-19-infected patients. Clinicians should be aware of this possible drug-related allergy, and it should be excluded as a cause of rash during FVP treatment of COVID-19.
Subject(s)
Amides/adverse effects , Antiviral Agents/adverse effects , Drug Eruptions/etiology , Pyrazines/adverse effects , Urticaria/chemically induced , Adult , Amides/administration & dosage , Antiviral Agents/administration & dosage , Female , Humans , Middle Aged , Pyrazines/administration & dosage , Young Adult , COVID-19 Drug TreatmentABSTRACT
BACKGROUND: In December 2020, Moderna released the mRNA-1273 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site. In addition, there have been dermatological adverse events, such as hypersensitivity reactions. Although rare, various bullous eruptions have been described following vaccination. Bullous pemphigoid has been reported to occur most often after receipt of influenza and the diphtheria-tetanus-pertussis vaccine. To the best of our knowledge, there have been no reports of bullous drug eruptions resulting from mRNA vaccines. CASE SUMMARY: A 66-years-old obese Guyanese male presented with a bullous rash following receipt of a commercial COVID-19 mRNA vaccine. He received the first dose uneventfully. However, within 24 h of receiving the second dose, he developed fever, myalgias, and malaise accompanied by a painful blistering rash of his torso, arms, and legs. His fever and myalgias improved after 24 h, but his painful rash did not, and five days after the initial symptoms, he presented to the hospital. There were many violaceous, poorly demarcated patches on his trunk, arms, and thighs on examination, many of which had large flaccid bullae within, and a few areas on his buttocks, posterior shoulder, and scrotum were eroded. The exam was also significant for lower extremity muscle tenderness, stiffness with preserved strength. A skin biopsy showed epidermal necrosis and sparse perivascular dermatitis concerning Stevens-Johnson syndrome or erythema multiforme. However, in the absence of mucous membrane involvement or targetoid lesions, the diagnosis of an extensive bullous fixed drug eruption was made. CONCLUSION: This case illustrates that the bullae eruption occurred as a result of receiving the Moderna vaccination.
Subject(s)
COVID-19 , Drug Eruptions , 2019-nCoV Vaccine mRNA-1273 , Aged , COVID-19 Vaccines , Humans , Male , RNA, Messenger , SARS-CoV-2ABSTRACT
We present an interesting and novel case of a de novo generalized pustular psoriasis following administration of first dose of Oxford-AstraZeneca COVID-19 vaccine in a patient with no pre-existing psoriasis or any previous dermatological issue.